Skip to main content
. Author manuscript; available in PMC: 2009 Apr 14.
Published in final edited form as: J Neuropathol Exp Neurol. 2008 Oct;67(10):1001–1010. doi: 10.1097/NEN.0b013e318188b204

FIGURE 8.

FIGURE 8

[3H]N-(2,5-dimethoxybenzyl)-N-(4-fluoro-2-phenoxyphenyl) acetamide (DAA1106) binding in human CNS disorders correlates with CD68-labeled but not GFAP-labeled cells. (A) [3H]DAA1106 Bmax values (y axis, in femtomoles per milligram) derived from tissues from patients with the disease conditions assessed and controls correlated with the abundance of CD68-labeled activated microglia (x axis, CD68 units) assessed in the same area in these same patients (r = 0.8259, p < 0.0001). (B) [3H]DAA1106 Bmax values (y axis, in femtomoles per milligram) did not correlate significantly with the extent of reactive astrocytosis (r = 0.1822, p = 0.2480).